Gene Expression Profiles in Patients With Permanent Atrial Fibrillation (AF) Versus Sinus Rhythm (SR)
Comparative Gene Expression Profiles in Patients With Permanent Atrial Fibrillation and Normal Sinus Rhythm
1 other identifier
observational
60
1 country
1
Brief Summary
The aim of this project is to determine the morphological criteria of apoptosis in atrial tissues of patients with AF versus SR at transcriptome and genomic size.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2008
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2008
CompletedFirst Submitted
Initial submission to the registry
September 1, 2009
CompletedFirst Posted
Study publicly available on registry
September 2, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2011
CompletedSeptember 3, 2009
September 1, 2009
September 1, 2009
September 2, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Expression profiles of genes related to apoptosis
6 months
Secondary Outcomes (1)
Expression profiles of pro-apoptotic and anti-apoptotic proteins
6 months
Study Arms (2)
AF
Patients with degenerative mitral valve regurgitation and permanent atrial fibrillation who require mitral valve repair or replacement.
SR
Patients with degenerative mitral valve regurgitation and maintaining sinus rhythm who require mitral valve repair or replacement.
Eligibility Criteria
Degenerative mitral valve regurgitation who require cardiac valve surgery
You may qualify if:
- Patients with permanent atrial fibrillation or sinus rhythm and degenerative mitral valve regurgitation who require cardiac surgery
- Pulmonary hypertension (systolic PA \> 45 mmHg)
- Left ventricular ejection fraction \> 30%
You may not qualify if:
- Paroxysmal AF or atrial flutter
- Second or third degree heart block
- Permanent pacemaker
- Wolff-Parkinson-White syndrome
- Brugada syndrome
- Ischemic or rheumatic mitral valve disease
- Dilated cardiomyopathy
- LVEF \< 30%
- Infective endocarditis, myocarditis
- Trauma
- Active HBV, HCV, HIV infection
- Chronic renal failure
- Autoimmune diseases
- Vasculitis
- Known genetic disorders
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ankara University Medical Faculty, Department of Cardiovascular Surgery,
Ankara, 06340, Turkey (Türkiye)
Related Publications (1)
Cubukcuoglu Deniz G, Durdu S, Dogan Y, Erdemli E, Ozdag H, Akar AR. Molecular Signatures of Human Chronic Atrial Fibrillation in Primary Mitral Regurgitation. Cardiovasc Ther. 2021 Oct 15;2021:5516185. doi: 10.1155/2021/5516185. eCollection 2021.
PMID: 34737791DERIVED
Biospecimen
Human atrial tissue
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
RUCHAN A AKAR, Assoc. Prof.
Ankara University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 1, 2009
First Posted
September 2, 2009
Study Start
December 1, 2008
Study Completion
December 1, 2011
Last Updated
September 3, 2009
Record last verified: 2009-09